Literature DB >> 30790116

Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy.

Syed R Latif1, Vinh Q Nguyen1,2, Dana C Peters1,3, Aaron Soufer1, Mariana L Henry1, Karl Grunseich4, Jeffrey Testani1, David J Hur1, Steffen Huber3, Hamid Mojibian3, Demetrius Dicks3, Albert J Sinusas1,3, Judith L Meadows1, Nikolaos Papoutsidakis1, Daniel Jacoby1, Lauren A Baldassarre5,6,7.   

Abstract

Hypertrophic cardiomyopathy (HCM) is associated with increased left ventricular (LV) mass, decreased myocardial strain, and the presence of LV fibrosis and scar. The relationship between LV scar and fibrosis with left atrial (LA) fibrosis in the setting of HCM has not been examined. The purpose of this study is to demonstrate a correlation between the degree of LA fibrosis and LV parameters in subjects with HCM. Twenty-eight subjects with HCM were imaged on a 1.5T MRI scanner with cine, LV and LA late gadolinium enhancement (LGE) sequences. LA LGE and LA measurements were correlated with LV measurements of volumes, mass, strain, and LGE. Other clinical conditions and medication usage were also examined and evaluated for correlation with LA and LV parameters. LV LGE was identified in 24 (86%) of the cases and LA LGE was identified in all of the cases. Extent of LA fibrosis significantly correlated with percent LV LGE (r = 0.64, p = 0.001), but not with indexed LV mass or maximum wall thickness. Extent of LA fibrosis also moderately correlated with decreased LV global strain (radial, r = - 0.50, p = 0.013; circumferential, r = 0.47, p = 0.02; longitudinal, r = 0.52, p = 0.013). Increased LA systolic volume correlated moderately with LV end diastolic volume (r = 0.50, p = 0.006). Patients on therapy with Renin-Angiotensin-Aldosterone System (RAAS) Inhibition had significantly less LA LGE compared to those without (18.6% vs 10.8%, p = 0.023). LA fibrosis, as measured by LGE, is prevalent in HCM and is correlated with LV LGE. The correlation between LA and LV LGE might suggest either that LA fibrosis is a consequence of LV remodeling, or that LA and LV fibrosis are both manifestations of the same cardiomyopathic process. Further study is warranted to determine the causality of LA scar in this population.

Entities:  

Keywords:  Hypertrophic cardiomyopathy; Left atrial fibrosis; Left ventricular late gadolinium enhancement; Left ventricular strain

Mesh:

Substances:

Year:  2019        PMID: 30790116     DOI: 10.1007/s10554-019-01551-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  7 in total

1.  Cardiovascular imaging 2019 in the International Journal of Cardiovascular Imaging.

Authors:  Johan H C Reiber; Gabriel T R Pereira; Luis A P Dallan; Hiram G Bezerra; Johan De Sutter; Arthur E Stillman; Nico R L Van de Veire; Joachim Lotz
Journal:  Int J Cardiovasc Imaging       Date:  2020-05       Impact factor: 2.357

2.  Left Atrial Strain Impairment Precedes Geometric Remodeling as a Marker of Post-Myocardial Infarction Diastolic Dysfunction.

Authors:  Jiwon Kim; Brian Yum; Maria C Palumbo; Razia Sultana; Nathaniel Wright; Mukund Das; Cindy You; Chaya S Moskowitz; Robert A Levine; Richard B Devereux; Jonathan W Weinsaft
Journal:  JACC Cardiovasc Imaging       Date:  2020-08-19

3.  Left atrial evaluation by cardiovascular magnetic resonance: sensitive and unique biomarkers.

Authors:  Dana C Peters; Jérôme Lamy; Albert J Sinusas; Lauren A Baldassarre
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-12-18       Impact factor: 6.875

4.  Speckle Tracking-Derived Left Atrial Stiffness Predicts Clinical Outcome in Heart Failure Patients with Reduced to Mid-Range Ejection Fraction.

Authors:  Ibadete Bytyçi; Frank L Dini; Artan Bajraktari; Nicola Riccardo Pugliese; Andreina D'Agostino; Gani Bajraktari; Per Lindqvist; Michael Y Henein
Journal:  J Clin Med       Date:  2020-04-25       Impact factor: 4.241

5.  Cost-Effectiveness Analysis of Evolocumab Therapy in Patients at High Risk of Cardiovascular Events in the Context of the Brazilian Unified Health System.

Authors:  Luiza Latado; Rodrigo Morel Vieira de Melo; Sóstenes Mistro; Adriana Lopes Latado; Harrison Floriano do Nascimento; Yasmin Menezes Lira; Natalia Ferreira Cardoso de Oliveira; Yuri de Santana Galindo; Tainá Viana; Luiz Carlos Santana Passos
Journal:  Arq Bras Cardiol       Date:  2021-11       Impact factor: 2.000

6.  Differences in Atrial Remodeling in Hypertrophic Cardiomyopathy Compared to Hypertensive Heart Disease and Athletes' Hearts.

Authors:  Helge Servatius; Simon Raab; Babken Asatryan; Andreas Haeberlin; Mattia Branca; Stefano de Marchi; Nicolas Brugger; Nikolas Nozica; Eleni Goulouti; Elena Elchinova; Anna Lam; Jens Seiler; Fabian Noti; Antonio Madaffari; Hildegard Tanner; Samuel H Baldinger; Tobias Reichlin; Matthias Wilhelm; Laurent Roten
Journal:  J Clin Med       Date:  2022-02-27       Impact factor: 4.241

7.  Atrial Mechanics in Hypertrophic Cardiomyopathy: Discriminating between Ventricular Hypertrophy and Fibrosis.

Authors:  Patrícia Marques-Alves; João André Ferreira; André Azul Freitas; José Paulo Almeida; Rui Baptista; Graça Castro; Rui Martins; Paulo Donato; Maria João Ferreira; Lino Gonçalves
Journal:  Arq Bras Cardiol       Date:  2022-01       Impact factor: 2.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.